SCHEMBL23215710

SCHEMBL23215710

N[C@@H](c1cc(Cl)c(Cl)cc1O)C1CCN(C(=O)[C@@H]2CCC(=O)NC2)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 2/20 0.37
HSD11B1 P28845 1/20 0.35
CNR1 P21554 7/20 0.35
NPSR1 Q6W5P4 2/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 3/20 0.32
DPP4 P27487 1/20 0.32
FAP Q12884 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
RORC P51449 1/20 0.32
TSHR P16473 1/20 0.32
SMYD3 Q9H7B4 1/20 0.32
CNR2 P34972 3/20 0.31
MGLL Q99685 1/20 0.31
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23215708 1.00 TACR3 (0.37) TACR3HSD11B1CNR1NPSR1HTT
SCHEMBL23230791 1.00 TACR3 (0.37) TACR3HSD11B1CNR1NPSR1HTT
SCHEMBL29745372 1.00 TACR3 (0.37) TACR3HSD11B1CNR1NPSR1HTT
SCHEMBL23215713 1.00 TACR3 (0.37) TACR3HSD11B1CNR1NPSR1HTT
Trifluoroacetic Acid SCHEMBL23215939 0.93 TACR3 (0.36) TACR3HSD11B1CNR1DPP4DPP8
Trifluoroacetic Acid SCHEMBL23215942 0.93 TACR3 (0.36) TACR3HSD11B1CNR1DPP4DPP8
SCHEMBL23230756 0.90 TLR9 (0.36) CNR1NPSR1HTTKMT2ADPP4
SCHEMBL23230974 0.90 TLR9 (0.36) CNR1NPSR1HTTKMT2ADPP4
SCHEMBL23230755 0.90 TLR9 (0.36) CNR1NPSR1HTTKMT2ADPP4
SCHEMBL30153569 0.90 TLR9 (0.36) CNR1NPSR1HTTKMT2ADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 TACR3 184/4885HSD11B1 1387/4885CNR1 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.